Kornimate/medical-research-clean huggingface dataset:
comparison of patients' satisfaction between dexmedetomidine and remimazolam anesthesia in patients with atrial fibrillation undergoing catheter ablation

Conditions: Patients With Atrial Fibrillation Undergoing Catheter Ablation

Summary: the primary purpose of this study was to investigate whether remimazolam administration for sedation had a positive effect on patients' satisfaction compared to dexmedetomidine administration in patients with atrial fibrillation undergoing catheter ablation. atrial fibrillation is a common arrhythmia in clinical practice. catheter ablation can be used when the cause of atrial fibrillation is in the pulmonary veins. however, the procedure takes 2 to 4 hours, and patients complain of considerable discomfort. remimazolam has the advantage of having no drug interaction with cyp3a4 and shorter elimination half-life, duration of action, and shorter recovery time than midazolam, a previously used drug. in addition, compared to dexmedetomidine, side effects such as bradycardia and hypotension are expected to be less. in addition, even if unexpected deep sedation is induced, complete reversal using flumazenil is possible, so the risk of re-sedation could be low. in other words, when remimazolam is used instead of a drug previously used as a sedative in atrial fibrillation patients undergoing catheter ablation, effects such as rapid action and recovery, reduced complications, improved safety, and improved patient satisfaction can be expected. therefore, this study was designed to confirm the hypothesis that administration of remimazolam would improve satisfaction in patients undergoing catheter ablation compared to dexmedetomidine.


Eligibility criteria:
inclusion criteria: * age 20-79 years, gender not limited * patients undergoing catheter ablation for atrial fibrillation who require monitored anesthetic care (mac). * patients with an american society of anesthesiologists (asa) physical status classification 1,2,3. exclusion criteria: * patients with an american society of anesthesiologists (asa) physical status classification \>3. * patients with a history of psychiatric disorders * patients with myocardial infarction or stroke within the past year * patients with a history of major vascular surgery or cardiac surgery within the past year * patients with reduced liver function, chronic kidney disease (stage 3 or higher) * patients diagnosed with heart failure with a left ventricular ejection fraction \<40% * patients who need vasopressor or oxygen therapy due to unstable vital signs before procedure. * patients with fever (\>38°) or severe uncontrolled high blood pressure * patients with a history of drug hypersensitivity during previous anesthesia * patients who are unable to communicate and have cognitive impairment * patients with a history of drug or alcohol addiction * patients with a history of obstructive sleep apnea
top set and parkinson's disease

Conditions: Parkinson Disease

Summary: this project will focus on improving power in adults with parkinson's disease, since power is related to performance of daily activities and memory and decision making. the study will compare traditional power training, where the participant does all exercises as fast as possible to top set resistance training, where the participant does power training, but it is preceded by warm-up sets that progress in weight until the participant reaches 90% of the person's maximum strength. if the top set method is better than traditional power training, it could be more beneficial than existing methods in improving independence in adults with parkinson's disease.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of parkinson's disease * between the ages of 30-90 years of age * a hoehn and yahr score of ≤3, which will be provided by the participant's medical provider within 1 year of the study's inception. exclusion criteria: * uncontrolled cardiovascular disease that prevents participation in a training program * documented hiv infection or another immunodeficiency syndrome * other neuromuscular diseases besides parkinson's disease * current musculoskeletal injury that prevents exercise. * having a pacemaker * pregnancy * incarcerated individuals * montreal cognitive assessment score below 18
vitamin e and pentoxifylline in treating women with lymphedema after radiation therapy for breast cancer

Conditions: Breast Cancer; Lymphedema

Summary: rationale: vitamin e and pentoxifylline may be effective in decreasing lymphedema in women who have received radiation therapy for breast cancer. purpose: randomized phase ii trial to determine the effectiveness of combining vitamin e and pentoxifylline in treating women who have lymphedema after receiving radiation therapy for breast cancer.

objectives: i. determine the effects of vitamin e and pentoxifylline on lymphedema in patients previously treated with radiotherapy for breast cancer. ii. compare the normal tissue injury and quality of life in patients treated with this regimen vs placebo. outline: this is a randomized, double-blind, placebo-controlled study. patients are randomized to one of two treatment arms. arm i: patients receive oral vitamin e and oral pentoxifylline twice daily for 6 months. arm ii: patients receive oral placebo twice daily for 6 months. quality of life is assessed at baseline and at 3, 6, 9, and 12 months. patients are followed at 6 and 12 months. projected accrual: a total of 100 patients (50 per treatment arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: prior diagnosis of breast cancer t1-3, n0-1, m0 prior radiotherapy to breast/chest wall plus axilla and/or supraclavicular fossa at least 2 years since prior radiotherapy no disease recurrence arm lymphedema due to prior radiotherapy reduced shoulder movement, induration in breast/chest wall, radiation-induced brachial plexopathy, symptomatic lung fibrosis, or non-healing wounds (including fractures) allowed as evidence of disability in addition to arm lymphedema hormone receptor status: not specified patient characteristics: age: not specified sex: female or male menopausal status: not specified performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: no liver failure renal: no renal failure cardiovascular: no ischemic heart disease no hypertension no hypotension no acute myocardial infarction no prior cerebral hemorrhage no prior retinal hemorrhage other: not pregnant negative pregnancy test fertile patients must use effective contraception no allergy to coconut oil prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: no concurrent insulin radiotherapy: see disease characteristics surgery: no prior axillary surgery lower axillary sampling allowed other: at least 3 months since prior daily vitamin e supplementation of more than 30 mg/day no prior pentoxifylline after radiotherapy no concurrent ketorolac or vitamin k no other concurrent vitamin e supplementation

Keywords: stage i breast cancer stage ii breast cancer stage iiia breast cancer lymphedema male breast cancer
a phase i study of the safety and pharmacokinetics of recombinant cd4 (rcd4) in patients with aids and aids-related complex

Conditions: HIV Infections

Summary: to determine the safety profile and maximum tolerated dose (mtd) of recombinant soluble human cd4 (rcd4) therapy in patients with aids or aids related complex (arc). to assess pharmacokinetic properties of rcd4 in humans. to obtain a preliminary indication of the antiviral effects of rcd4 in patients with aids and aids related complex (arc).


Eligibility criteria:
inclusion criteria patients must have: * hiv-1 seropositivity. * diagnosis of aids or aids related complex (arc). * failure to tolerate or respond to zidovudine (azt) or decided to decline azt therapy. * the ability to sign a written informed consent form prior to treatment. * a willingness to abstain from all other experimental therapy for hiv infection during the entire study period. * a life expectancy of at least 3 months. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * serious active opportunistic infections. * malignancies other than kaposi's sarcoma. concurrent medication: excluded: * zidovudine (azt). * corticosteroids. * nonsteroidal anti-inflammatory agents (nsai). * other experimental therapy. patients with the following are excluded: * serious active opportunistic infections. * malignancies other than kaposi's sarcoma. prior medication: excluded within 3 weeks of study entry: * zidovudine (azt). * chemotherapy. * immunomodulators. * other experimental therapy.

Keywords: recombinant proteins acquired immunodeficiency syndrome antigens, cd4 aids-related complex
individualized pharmaceutical-care in outpatients with cancer pain

Conditions: Cancer Pain

Summary: the purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant outpatients

this study is a prospective multicenter randomized controlled study to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant outpatients treated with sustained released morphine, oxycodone, and transdermal fentanyl.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older; * histologically confirmed solid tumor; * diagnosed chronic cancer pain; * opioid-tolerant patients; * overall survival is expected to be over 3 months; * karnofsky performance score≥50; * willing and able to comply with the protocol exclusion criteria: * patients aged 18 years or older; * histologically confirmed solid tumor; * diagnosed chronic cancer pain; * opioid-tolerant patients; * overall survival is expected to be over 3 months; * karnofsky performance score≥50; * willing and able to comply with the protocol

Keywords: pharmaceutical care adherence
study to evaluate the safety and efficacy of ba058 (abaloparatide) for prevention of fracture in postmenopausal women

Conditions: Osteoporosis; Postmenopausal Osteoporosis

Summary: the purpose of this study is to determine whether ba058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.

this is a randomized, double-blind, placebo-controlled, comparative phase 3, multicenter international study to evaluate the efficacy and safety of ba058 (abaloparatide) 80 µg in the prevention of fracture in otherwise healthy ambulatory postmenopausal women with severe osteoporosis.

Eligibility criteria:
inclusion criteria: * healthy ambulatory postmenopausal (≥ 5 years) women from 50 to 85 years of age (inclusive) with a diagnosis of osteoporosis * the women are to have a bone mineral density (bmd) t score ≤ -2.5 and \> -5.0 at the lumbar spine or hip (femoral neck) by dual energy x-ray absorptiometry (dxa) and radiological evidence of 2 or more mild or one or more moderate lumbar or thoracic vertebral fractures, or history of low trauma forearm, humerus, sacral, pelvic, hip, femoral, or tibial fracture within the past 5 years. postmenopausal women older than 65 who meet the above fracture criteria but have a t score ≤ -2.0 and \> -5.0 may be enrolled. women older than 65 who do not meet the fracture criteria may also be enrolled if their t score is ≤ -3.0 and \> -5.0 * normal physical exam, vital signs, electrocardiogram (ecg) and medical history * laboratory tests within the normal range including serum calcium, pth(1-84), serum phosphorus and alkaline phosphatase exclusion criteria: * history of more than 4 mild or moderate spine fractures or any severe fracture * abnormality of the spine or hip that would prohibit assessment of bone mineral density (bmd) * unexplained elevation of serum alkaline phosphatase, history of bone disorders (such as paget's disease) or a diagnosis of cancer within the last 5 years (with the exception of basal cell or squamous cancer of the skin) * history of thyroid, parathyroid, or adrenal disorders, or malabsorptive syndromes or any chronic or recurrent diseases or disturbances that would interfere with the interpretation of study data or compromise the safety of the patient * prior treatment with parathyroid hormone (pth) or parathyroid hormone-related peptid (pthrp) * prior treatment with bisphosphonates, fluoride, or strontium within the past five years or treatment with androgens, anabolic steroids, corticosteroids or selective estrogen receptor modulators within the past 12 months (except hormone replacement therapy) * prior treatment with an investigational drug within the past 12 months * history of nephrolithiasis or urolithiasis within the past five years, or history of osteosarcoma at any time

Keywords: ba058 abaloparatide abaloparatide-sc osteoporosis postmenopausal bone loss active fracture
stereotactic body radiotherapy (sbrt) for medically inoperable localised renal tumors (sabina trial)

Conditions: Kidney Neoplasm; Renal Cancer; Inoperable Disease; SBRT; SABR

Summary: study evaluating the activity and efficacy of stereotactic body radiotherapy for the treatment of medically inoperable localized renal cancer

stereotactic body radiotherapy (sbrt) is a non-invasive alternative to surgery to control localized primary renal cell cancer (rcc) in medically inoperable patients. the kidney tumor has classically been considered radioresistant. multiple retrospective series and few phase ii trial have studied the role of sbrt in localized renal tumors with favorable outcomes. although large prospective studies are lacking, we evaluate the safety and effectiveness of sbrt for the treatment of renal cancer. participants will be allocated to recieve either single 26gy fraction or multifraction 3 - 5 fraction-squeme. assesment at regular intervals will estimate the activity and efficacy of the technique, evaluate tolerability, estimate survival, estimate distant failure rate, and renal function change after sabr. follow-up visits occur at 1month and every 3 months in the first year after sbrt, then every 6 months in the second year and then yearly until study closure.

Eligibility criteria:
inclusion criteria: * histological diagnosis of renal tumor and/or highly suspected malignant neoplasm by ct, mri or pet. * tumor diameter \>1cm - \<7cm * tumor visible on ct planning * medically inoperable disease (or rejection of surgery) * karnofsky index \>70% * \>18 y.o. * informed consent signature exclusion criteria: * non-oncological renal disease or autoinmunological disorder that does not recommend the treatment with radiotherapy. * previous local/regional rt * life expectancy \<6 months * concomitance with other antineoplastic drugs

Keywords: stereotactic body radiotherapy renal cancer primary localized renal cancer kidney neoplasm radiotherapy inoperable cancer stereotactic ablative radiotherapy sbrt sabr
observational study:safety,efficacy and quality of life of patients with atrial fibrillation, treated with trombix®

Conditions: Atrial Fibrillation

Summary: the rational behind this observational study is to collect real life data about the use of trombix® (rivaroxaban) among patients with atrial fibrillation in algeria . the aim is to evaluate the safety, efficacy and quality of life.

trombix® (rivaroxaban) is used for the treatment of patients with atrial fibrillation. beker laboratories are conducting an observation study to evaluate its use among algerian population in regards to its safety, efficacy and the quality of life of patients after its use.

Eligibility criteria:
inclusion criteria: * patient, male or female, aged ≥ 19 years. * patient with a diagnosis of atrial fibrillation who requires treatment with trombix® or switch of anti-vitamin k treatment totrombix® (patient not balanced with current treatment or wishing to change treatment with better manageability). * patient being able to provide free and informed written consent before the study. exclusion criteria: * hypersensitivity to the active ingredient or to one of the excipients indicated in the summary of product characteristics of trombix® * clinically significant progressive bleeding. * injury or illness, if considered to be at significant risk of major bleeding. this may include: current or recent gastrointestinal ulceration, presence of malignant tumors with a high risk of bleeding, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intra-spinal or intracerebral vascular anomalies. * concomitant treatment with any other anticoagulant, for example, unfractionated heparin (ufh), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran exilate, apixaban, etc.) except in specific circumstances of switching from anticoagulant treatment or in the case of administration of ufh at doses necessary to maintain the permeability of a central venous or arterial catheter. * liver injury associated with coagulopathy and clinically significant bleeding risk, including cirrhotic patients with child pugh score class b or c. * pregnancy and breast feeding

Keywords: real life observational safety efficacy
ccrt with twice weekly paclitaxel and cisplatin followed by surgery for locally advanced esophageal cancer

Conditions: Esophageal Cancer

Summary: ccrt with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.

the purpose of this study is to find out the clinical and pathological response rates of pre-operative concurrent chemoradiotherapy (ccrt) with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.

Eligibility criteria:
inclusion criteria: 1. pathologically proven scc or adenocarcinoma of esophagus . 2. locally advanced esophageal cancer , defined as t3 and/or n1 disease.( ajcc 1998) 3. m1a disease defined ( ajcc 1998) , including celiac lymph node for lower thoracic esophageal cancer and cervical lymph node involvement for upper thoracic esophageal cancer . 4. age ≧ 18 ys 5. kps ≧ 60% 6. hemogram : wbc ≧ 4000/mm3 or anc ≧ 2000 /mm3 and platelet ≧ 100,000/mm3 . biochemistry : got/gpt ≦ 3.5 times , cr ≦ 1.5 mg/dl and bilirubin ≦ 2.0 mg/dl . exclusion criteria: 1. invasion to surrounding organ ( t4 disease ) . 2. distant metastasis , except m1a disease . 3. patients who refuse operation .

Keywords: concurrent chemoradiotherapy esophageal cancer
safety study of bez235 with everolimus in subjects with advanced solid tumors

Conditions: Cancer

Summary: the purpose of this clinical trial is to determine the effects good or bad of combining bez235 along with everolimus to determine if it is a safe treatment for patients with advanced cancers of different types.

bez235 is an agent that was developed to slow down or halt cell growth and proliferation. it works by inhibiting two pathways that are important for cell growth and replication, one is called mtor and the other is called pi3k. everolimus is an agent that also targets mtor thus also slows down cell growth and spread; in addition, it injures blood vessels that supply cancer cells with nutrition. the rationale behind combining everolimus with bez235 is to inhibit cell growth and halt cancer spread by greater degree than either drug alone. bez235 is not approved by the fda for use in humans outside the context of a clinical trial. everolimus is fda approved for the treatment of renal cell carcinoma (kidney cancer), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (ts), and advanced neuroendocrine tumors of pancreatic origin (pnet).

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed advanced solid malignancies that are metastatic or unresectable, and for which standard/curative measures do not exist by recist 1.1 measureable lesion which is not declining * age ≥ 18 years old at the day of consenting to the study * eastern cooperative oncology group (ecog) performance status less than or equal to 2 * adequate bone marrow and organ function as defined by laboratory values exclusion criteria: * previous treatment with pi3k inhibitors * concurrent malignancy or has a malignancy within 3 years of study enrollment, (with the exception of adequately treated basal or squamous cell carcinoma or cervical carcinoma in situ) * concurrently using other approved or investigational antineoplastic agent * currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, hormonal therapy, etc.) * poorly controlled diabetes mellitus (hba1c \> 8 %) * chronic treatment with systemic steroids or another immunosuppressive agent * active cardiac disease * inadequately controlled hypertension (i.e, sbp \>180 mmhg or dbp \>100mmhg) * impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of bez235 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea grade ≥ 2, malabsorption syndrome, or small bowel resection)

Keywords: solid tumor glioblastoma multiforme gbm brain tumor neuroendocrine tumor
characterizing the microvascular environment of bladder cancer with super-resolution ultrasound localization microscopy

Conditions: Bladder Cancer

Summary: the project will include 30 patients with bladder cancer who are candidates for bladder removal. after signing the consent form, the study team will collect some clinical data, such as age, past medical history, past surgical history, and information about your current disease. at the day of surgery, after putting participants into sleep and before surgery begins, the study team will do a novel ultrasound called "super-resolution ultrasound localization microscopy" to check if there is still disease in the bladder. the team will then compare the results of this investigational ultrasound with the final pathology and other imaging studies.


Eligibility criteria:
inclusion criteria: * adults \> 18 years * histological evidence of urothelial cancer of the bladder for which radical cystectomy is recommended as per the treating physician (e.g., mibc or high-risk nmibc, such as high-grade t1 bcg refractory and worrisome histological variants) exclusion criteria: * known or suspected hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (peg). * pregnancy or breastfeeding * decline to participate in the study * participants who had serious allergic reactions to covid-19 vaccination. * participants with unstable conditions such as hospital in-patients, icu patients, or high-risk cardiac diseases.